Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2012
Phase Ib/IIa clinical trial of a new medicinal product of the somatic cell therapy class (eASCs). This study is designed as a multicenter, single blind, fixed dose escalation, with three treatment groups, controlled with placebo (randomization 3:1) whose target population are patients with rheumatoid arthritis refractory to at least two biologic.
Epistemonikos ID: 0679e449487a71fc0ae86256e72d179410772bc2
First added on: Mar 23, 2022